Cosmo Godino on DOAC Use in AF: Association With Acute Thromboembolic and Bleeding Events
Cosmo Godino, Interventional Cardiologist at Heart Valve Center, IRCCS San Raffaele Hospital, shared on LinkedIn:
”Is your blood thinner at the right level?
For years we’ve treated direct oral anticoagulants (DOACs) as “set and forget” drugs.
Routine monitoring wasn’t considered necessary. But the 4Levels Study challenges this assumption.
In 1 794 patients with atrial fibrillation presenting to the emergency department, we measured DOAC plasma levels at the exact moment they came in.
The findings are striking:
- Low drug levels ≈ doubled risk of thrombosis: half of all thromboembolic events occurred in patients with DOAC levels in the lowest quartile, versus 26 % of controls.
- High drug levels ≈ doubled risk of bleeding: 46 % of bleeding events occurred in patients with levels in the highest quartile, versus 23 % of controls.
- These associations held across all four DOACs studied; odds of thrombosis or bleeding were about twice as high at the extremes.
This isn’t about trough or peak levels—it’s about drug levels at the moment patients are having strokes or spontaneous bleeds.
The controversial question: should we start monitoring DOAC levels in selected high‑risk patients? It’s too early to change practice, but the “one‑size‑fits‑all” approach may not be serving everyone.
Controlled trials are needed before any change in guidelines.
Proud to share this work with an incredible team.”
Read the full paper in JTH.
Article: Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events
Authors: Cosmo Godino, Riccardo Mazza, Carlo Gaspardone, Alessia Minerva, Rachele Sena, Gianmarco Cozzani, Anna Salerno, Michela Cera, Massimo Slavich, Leila Anna De Lorenzo, Giulio Leo, Giulia Nemola, Annalisa Fattorini, Luciano Crippa, Patrizia Della Valle, Alberto Margonato, Armando D’Angelo

Stay updated on all scientific advances in the field with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera
